Drug intelligence / Profile preview

compound xiwujia granule

Development stage: Unknown
Lead developer: Heilongjiang Quanle Pharmaceutical
Administration: Oral

Overview

Compound Xiwujia Granule is a traditional Chinese medicine formulation investigated for the treatment of chronic fatigue syndrome. It is administered as an oral granule and has been studied in randomized, double-blind clinical trials to assess its efficacy in improving symptoms measured by the Chalder Fatigue Scale. The mechanism of action is not fully elucidated but, as a multi-herbal preparation, it likely exerts effects through modulation of immune function and improvement of energy metabolism. The product is developed and manufactured by Heilongjiang Quanle Pharmaceutical.

Brand names: compound xiwujia granules
Other names: compound ciwujia granule

Beyond the preview

Go deeper on compound xiwujia granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound xiwujia granule.

Explore the full profile